Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

Elena Fountzilas, G. Koumakis, Ioannis Boukovinas et al.|ESMO Open|2020

Cited by 38